An interventional study of Phantom System in Osteoarthritis of the Knee, sponsored by Moximed. Terminated at 4 sites in 2 countries. Open to participants aged 25 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-11-18.
Sponsored by Moximed · Not applicable, Interventional, and Treatment
Adequate data has been collected
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 78 studies in Osteoarthritis, Knee with a site in Poland — 12 open to participants now, 13 under way, 2 of them phase 3. Osteoarthritis, Knee · Poland.
Among the 78 studies in Osteoarthritis, Knee with a site in Poland, this one is the 69th largest by enrollment of the 72 interventional ones that give a count, is one of 2 that started in 2014, is one of 28 with no phase, and was the 10th registered.
3,297 studies on the registry are indexed under Osteoarthritis, Knee; 624 are open to participants now.
Browse Osteoarthritis, Knee studies →12 of the 78 studies in Osteoarthritis, Knee with a site in Poland are open now. Recruiting first, the newest first:
Medical University of Warsaw · Sites in Poland
Ages 18+
Implai Sp z o.o · Sites in Poland
Ages 18+
Implai Sp z o.o · Sites in Poland
Ages 18+
Poznan University of Medical Sciences · Sites in Poland
Ages 60–100
Novo Nordisk A/S · Sites in Poland, United States, Australia and 8 more countries
Ages 18+
A study can be open while its sites in Poland have not opened yet or have stopped. Only those recruiting at a site in Poland →
Of the 385 Osteoarthritis, Knee studies recruiting now, 178 (46%) set no upper age limit and 114 (30%) stop at 75 or younger; 19 take children under 18; 39 take healthy volunteers.
This study: 25 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
78 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 16 · Phase 3 16 · Phase 4 10
First in 2007; this study’s year is marked. 2 started in 2014.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 40 is below the median of 68 across 2,719 interventional studies indexed under Osteoarthritis, Knee.
Median enrollment 115 across the 72 interventional studies, 131 across the 6 observational. Of the 58 that completed or were terminated, 22 (38%) have results posted.
This tab as a report to print or save as PDF → With an account.
42 of 78 have an industry lead sponsor. The 10 most frequent:
Moximed is the lead sponsor of 9 studies on the registry; 2 are open to participants now.
Moximed has 7 studies filed under Osteoarthritis, Knee — fewer than ten, so there is no comparison to draw.
3 of the studies in Osteoarthritis, Knee with a site in Poland that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07449442Poznan University of Medical SciencesSII Levels Following iPACK Block With Adductor Canal Block in Knee Arthroplasty | 2026-11-30 |
| NCT07813078University of RzeszowAnti-Gravity Treadmill Gait Training for Knee Osteoarthritis | 2026-12-31 |
| NCT07677215Poznan University of Medical SciencesACB and iPACK Blocks With Intravenous Dexamethasone and Perineural Dexmedetomidine in Total Knee Arthroplasty | 2027-09-01 |
Add all 3 to your calendar (.ics) → With an account.
Among the 78 studies in Osteoarthritis, Knee with a site in Poland, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate improvement in pain and function following implantation of a new device, called the Phantom Knee System, in patients needing unloading of the medial compartment of the knee
This is a prospective, multi-center, single-arm, first in human (FIH) study. Patients will be asked to participate in the study and follow up for a 24 month period following implantation of the study device.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Previous joint modifying surgery in the target knee within 12 months prior to planned surgery date such as ligament reconstruction or meniscus repair, cartilage transplantation, and microfracture
a) Arthroscopic surgeries for joint lavage, meniscectomy, chondral debridement, and loose body removal are excluded if within 3 months prior to planned surgery date
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients will be treated with the Phantom Knee System device
Device: Phantom System
Unloading of medial knee compartment with Phantom System
Also known as: Phantom Knee System
Number of Participants With Clinically Significant Improvement in WOMAC Pain
The number of participants with clinically significant improvement in WOMAC pain of at least 20% and ≥10 points from baseline to 24 months. WOMAC pain derived from the KOOS questionnaire.
Time frame: Baseline and 24 months
Number of Participants With Clinically Significant Improvement in WOMAC Function
The number of participants with clinically significant improvement in WOMAC function of at least 20% and ≥10 points from baseline to 24 months. WOMAC function derived from the KOOS questionnaire.
Time frame: Baseline and 24 months
40 subjects (30 in Poland and 10 in South Africa, N=14 in Phase 1 (Phantom FIH) and N=26 in Phase 2 (Phantom High Flex)
| Milestone | Phantom First in Human (FIH) | Phantom High Flex |
|---|---|---|
| Started | 14 | 26 |
| Completed | 14 | 26 |
| Not completed | 0 | 0 |
The number of participants with clinically significant improvement in WOMAC pain of at least 20% and ≥10 points from baseline to 24 months. WOMAC pain derived from the KOOS questionnaire.
| Participants | Phantom First in Human (FIH) | Phantom High Flex |
|---|---|---|
| Number of Participants With Clinically Significant Improvement in WOMAC Pain | 10 | 25 |
The number of participants with clinically significant improvement in WOMAC function of at least 20% and ≥10 points from baseline to 24 months. WOMAC function derived from the KOOS questionnaire.
| Participants | Phantom First in Human (FIH) | Phantom High Flex |
|---|---|---|
| Number of Participants With Clinically Significant Improvement in WOMAC Function | 10 | 24 |
Collected over Adverse Events collected from enrollment through 24 month visit.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Phantom First in Human (FIH) | 0/14 (0%) | 4/14 (28.6%) | 4/14 (28.6%) |
| Phantom High Flex | 0/26 (0%) | 5/26 (19.2%) | 7/26 (26.9%) |
| Event | Phantom First in Human (FIH) | Phantom High Flex |
|---|---|---|
| Related - Mechanical failure - femoral ball dislocationSurgical and medical procedures | 3/14 | 0/26 |
| Related - Knee painMusculoskeletal and connective tissue disorders | 1/14 | 2/26 |
| Related - Mechanical failure of device or componentsSurgical and medical procedures | 1/14 | 0/26 |
| Unrelated - Other: OA PainMusculoskeletal and connective tissue disorders | 1/14 | 0/26 |
| Unrelated - Myocardial InfarctionCardiac disorders | 1/14 | 0/26 |
| Unrelated - Knee PainMusculoskeletal and connective tissue disorders | 0/14 | 1/26 |
| Unrelated - PneumoniaRespiratory, thoracic and mediastinal disorders | 0/14 | 1/26 |
| Unrelated - Other: Bleeding from uteral myomasReproductive system and breast disorders | 0/14 | 1/26 |
| Event | Phantom First in Human (FIH) | Phantom High Flex |
|---|---|---|
| Related - Knee painMusculoskeletal and connective tissue disorders | 1/14 | 3/26 |
| Related - Audible clicking, squeaking, or other noise associated with deviceProduct Issues | 0/14 | 2/26 |
| Related - Bone lossMusculoskeletal and connective tissue disorders | 0/14 | 2/26 |
| Related - ROM insufficient or limitedMusculoskeletal and connective tissue disorders | 1/14 | 2/26 |
| Related - Inflammation - OtherMusculoskeletal and connective tissue disorders | 1/14 | 0/26 |
| Unrelated - Other: Contralateral Knee PainMusculoskeletal and connective tissue disorders | 1/14 | 0/26 |
Enrolled Population
| Age, Continuous(years) | Phantom First in Human (FIH) | Phantom High Flex | Total |
|---|---|---|---|
| Mean | 50.5 ± 9.5 | 50.9 ± 8.8 | 50.8 ± 8.9 |
| Sex: Female, Male(Participants) | Phantom First in Human (FIH) | Phantom High Flex | Total |
|---|---|---|---|
| Female | 5 | 10 | 15 |
| Male | 9 | 16 | 25 |
| Race (NIH/OMB)(Participants) | Phantom First in Human (FIH) | Phantom High Flex | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 |
| White | 13 | 25 | 38 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 1 | 1 | 2 |
| Region of Enrollment(participants) | Phantom First in Human (FIH) | Phantom High Flex | Total |
|---|---|---|---|
| South Africa | 4 | 6 | 10 |
| Poland | 10 | 20 | 30 |
| BMI((kg/m^2)) | Phantom First in Human (FIH) | Phantom High Flex | Total |
|---|---|---|---|
| Mean | 28.0 ± 4.2 | 28.4 ± 3.2 | 28.3 ± 3.5 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Undecided
Ran from Oct 2014 to primary completion in Nov 2017, 37 months.
Results were first posted in Nov 2026, 9 years after primary completion.
How these figures are worked out, and which studies are left out of them.
Adequate data has been collected
Adequate data has been collected
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is terminated, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Moximed